초록 ▼

1. 슬관절 골관절염 환자에 대한 구미강활탕한약제제의 임상효과 및 안전성에 대한 다기관임상시험방법; 무릎 골관절염 환자를 대상으로 무작위 대조군 이중맹검 2상 임상시험하여, 환자의 pain VAS,WOMAC score,및 부작용을 분석함
결과; 총 128명의 환자(투약군 62명, 위약군 66명)를 분석함. 투약후 2주째부터 투약군에서 pain VAS와 총 WOMAC score가 위약군에 비해 의미있게 감소하였고, 4주후에는 그 차이가 더 현저하였으며, 투약중지후 2주째에도 pain VAS와 총WOMAC(강직 부항목 제외)의 의

1. 슬관절 골관절염 환자에 대한 구미강활탕한약제제의 임상효과 및 안전성에 대한 다기관임상시험방법; 무릎 골관절염 환자를 대상으로 무작위 대조군 이중맹검 2상 임상시험하여, 환자의 pain VAS,WOMAC score,및 부작용을 분석함
결과; 총 128명의 환자(투약군 62명, 위약군 66명)를 분석함. 투약후 2주째부터 투약군에서 pain VAS와 총 WOMAC score가 위약군에 비해 의미있게 감소하였고, 4주후에는 그 차이가 더 현저하였으며, 투약중지후 2주째에도 pain VAS와 총WOMAC(강직 부항목 제외)의 의미있는 감소를 유지함. 부작용 분석에서는 2%이내의 일시적 소화불량 등이 있었으나 통계적 차이가 없었다.
결론; 슬관절 골관절염 환자에서 구미강활탕은 효과적이고 안전하게 사용되어질 수 있다고 사료됨.
2. 슬관절 골관절염의 음양한열허실 변증지침 개발
슬관절 골관절염에 대한 임상적 증상과 증후를 분석하고 전문가의 의견을 모아 엄격한 신체검진상에서 동통, 압통, 부종, 열감, 발적, 골염발음, 관절변형, 관절가동범위제한,대퇴사두근 약화 및 위축을 토대로 한방적 관점에서 재분류하여 관절 자체의 객관적 증상과 증후에 따른 寒熱虛實 辨證을 제시

Abstract ▼

1. Clinical efficacy and safety of Gumiganghwaltang in patients with knee osteoarthritis Objectives: The objectives of this study were to determine the efficacy and safety of Gumiganghwaltang in pain reduction and functional improvement in patients with knee osteoarthritis (OA).
Design: This was

1. Clinical efficacy and safety of Gumiganghwaltang in patients with knee osteoarthritis Objectives: The objectives of this study were to determine the efficacy and safety of Gumiganghwaltang in pain reduction and functional improvement in patients with knee osteoarthritis (OA).
Design: This was a prospective, randomized, controlled, double-blinded, phase 2 clinical trial. The study was conducted at the Soonchenhyang university Cheonan hospital and Gyungwon Gil hospital. Patients with knee osteoarthritis, who fulfilled the “ "American College of Rheumatology ” " (ACR) classification of idiopathic osteoarthritis of knee and radiographic criteria were randomly selected and enrolled for the study. After initial screening and resting period, Gumiganghwaltang and similar identical placebo were administered. Pain intensity at second, and sixth weeks of study as well as 2week after discontinuation of drugs was assessed by using 100 mm visual analogue scale (VAS). Changes in the Korean version of the Western Ontario and McMaster Universities (K-WOMAC) index score were compared at the initiation and completion of the study.
Results: 62and 66patients were randomized to Gumiganghwaltang and similar identical placebo respectively. There was no difference of VAS and WOMAC scores between groups in baseline. VAS assessed by patients were significantly reduced after Gumiganghwaltang administration in 2,4, weeks and as well as 2week after discontinuation of drugs. Results showed an improvement in the pain and physical function of K-WOMAC scale which was significantly higher in Gumiganghwaltang than placebo group, and decreases of total K-WOMAC score were also significantly higher in Gumiganghwaltang groups than placebo group in in 2weeks. In 4 weeks after, all score of K-WOMAC score included total, pain, stiffness, and function were marked improved. Two week after discontinuation of Gumiganghwaltang, The effect was maintained in the pain and physical function of K-WOMAC scale , but not stiffness scale. No serious adverse effect was observed, and there was no difference in incidence of adverse effect between Gumiganghwaltang and placebo groups. In this population of Korean patients with knee osteoarthritis,Gumiganghwaltang was found to be safe, tolerable and effective for symptomatic improvement of pain and physical function.
Conclusions: Gumiganghwaltang was efficacious and safe for the treatment of knee OA.
2. Development of Palgangbyeonjeung guidelines knee osteoarthritis.
We Development of Palgangbyeonjeung guidelines knee osteoarthritis.
Palgangbyeonjeungeul of Traditional Korean Medocine combined with physical examination of modern medicine.
First, Accurate physical examination is conducted in the following items: Pain, Tenderness, Swelling, Heating, Redness, Bony crepitus, Tactile Bony spur, Deformity Limit of motion, Muscle weakness or artophy And then, It was classified based on the palgangbyeonjeung.
Sil-jeun - more than moderate pain
or tenderness
or any of soft tissue swelling
or any of fluid swelling
Heo-jeung - Chronic (more than 6 week) mild pain & tenderness
or any of muscle weakness
or any of muscle atrophy
or bony crepitus > ++
(If there is only one demonstration of the sil-jeun, designatured to
sil-jeun category)
Han-jeung - Any of deformity
or any of limit of motion
(Designatured to Yeoljeung category with Heating, Redness)
Yeol-jeung- Any of Heating
or redness

목차 Contents

• 1. 겉표지 (앞면) ... 1
• 1. 겉표지 (측면, 뒷면) ... 2
• 2. 제출문 ... 3
• 3. 보고서 요약서 ... 4
• 4. 요약문 (한글) ... 5
• 5. 요약문 (영문) ... 7
• 6. 연구 성과 실적 및 향후 계획 ... 9
• 7. 참여연구원 현황표 ... 15
• 목차 ... 16
• Ⅰ. 총괄현황 ... 18
• 1. 겉표지 (앞면) ... 19
• 1. 겉표지 (측면, 뒷면) ... 20
• 2. 제출문 ... 21
• 3. 보고서 요약서 ... 22
• 4. 요약문 (한글) ... 23
• 5. 요약문 (영문) ... 24
• 6. 연구 성과 실적 및 향후 계획 ... 25
• 7. 참여연구원 현황표 ... 38
• Ⅱ.총괄연구과제 연구결과 ... 39
• 1. 연구개발과제의 배경 및 필요성 ... 40
• 2. 국내외 기술개발 현황 ... 50
• 3. 연구개발과제의 추진체계 ... 54
• 5. 목표별 성과지표 ... 55
• 6. 추진전략 및 일정 ... 56
• 4. 연구개발수행 내용 및 결과 ... 68
• 5. 목표달성도 및 관련분야 기여도 ... 94
• 6. 향후 연구성과 추진 계획(※해당되는 경우만 작성) ... 97
• 7. 연구개발결과의 파급효과 ... 98
• 8. 연구개발결과의 활용계획 ... 100
• 9. 연구개발과정에서 수집한 해외과학기술정보 ... 101
• 10. 참고문헌 ... 101
• Ⅱ-○.제○세부연구과제 ... 107
• 1. 연구개발과제의 목표 ... 108
• 2. 연구개발과제의 추진체계 ... 108
• 3. 연구개발수행 내용 및 결과 ... 108
• 4. 참고문헌 ... 108
• Ⅲ. 첨부서류 ... 109
• 1. 자체평가의견서 ... 111
• 2. 실적 증빙자료 ... 117
• 3. 기타 첨부서류 ... 117